CD4 and melanoma: Recent reports that emphasize the role of CD4+ T cells in determining the clinical outcome of immune checkpoint blockade in patients with NSCLC (3) and melanoma (26) are of particular relevance in the context of the UV1 vaccine, which is designed to elicit CD4+ T cell responses.